Nitin Ohri, MD, MS

home / authors / nitin-ohri-md-ms

Nitin Ohri, MD, MS, is a professor of radiation oncology at Montefiore Einstein Comprehensive Cancer Center

Articles

Nitin Ohri, MD, MS, professor, radiation oncology, Montefiore Einstein Comprehensive Cancer Center

Personalizing Lung Cancer Treatment Reduces Toxicity and Improves Cure Rates

Nitin Ohri, MD, MS
May 8th 2025

New lung cancer treatment options have emerged, and several groups are exploring treatment strategies that omit chemotherapy for locally advanced NSCLC.

Read More

Nitin Ohri, MD, MS

A Gut Check on the Digital Divide: How Wearable Devices Are Changing Cancer Care

Nitin Ohri, MD, MS
January 6th 2022

The idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.

Read More

Nitin Ohri, MD, of Montefiore Medical Center

Dr. Ohri on the Role of Chemoradiation in Locally Advanced NSCLC

Nitin Ohri, MD, MS
January 26th 2021

Nitin Ohri, MD, discusses the role of chemoradiation therapy in locally advanced non–small cell lung cancer.

Read More

Latest Updated Articles

Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Vivek G Patel, MD
Published: April 2nd 2025 | Updated: May 2nd 2025
Dr Patel on Choosing Between Mosunetuzumab and Epcoritamab in Follicular Lymphoma
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer